# SUPHA PHARMACHE (NSE: SUPHA) share price, financials and shareholding

Source: https://app.pivotnow.in/stock/SUPHA · Pivot · prices to 22 Oct 2026

With a market capitalisation of ₹25 Cr, it ranks 3477th by market cap among the 4,183 NSE companies Pivot tracks (a small-cap company by SEBI's rank bands). It belongs to the Pharma & Healthcare sector; its industry is Drug Manufacturers - Specialty & Generic.

Its return on equity was 4.9% in FY25. In Q2 FY26, the quarter ended 30 Sep 2025, revenue was ₹111 Cr and net profit ₹9 Cr, on a consolidated basis. Promoters held 1.13% of the company as of 31 Dec 2025.

## Key numbers

| Metric | Value |
| --- | --- |
| Market cap | ₹25 Cr |
| ROE | 4.9% (FY25) |
| ROCE | 22.0% (FY25) |
| Debt to equity | 26.01 |

## Quarterly results (₹ crore, consolidated)

| Quarter | Revenue | Revenue YoY | Net profit | Net profit YoY | EPS (₹) |
| --- | --- | --- | --- | --- | --- |
| Q2 FY26 | ₹111 Cr | — | ₹9 Cr | — | ₹0.10 |
| Q1 FY26 | ₹113 Cr | — | ₹5 Cr | — | ₹0.05 |

## Annual results (₹ crore)

| Fiscal year | Revenue | Net profit |
| --- | --- | --- |
| FY25 | ₹223 Cr | ₹2 Cr |
| FY24 | ₹4,042 Cr | ₹33 Cr |
| FY23 | ₹510 Cr | ₹5 Cr |
| FY22 | ₹505 Cr | ₹1 Cr |
| FY21 | ₹90 Cr | ₹0 Cr |
| FY20 | ₹3 Cr | ₹0 Cr |

## Shareholding (31 Dec 2025)

- Promoters: 1.13%
- Foreign institutions: 1.70%
- Non-institutions: 97.17%

## Peers

| Company | Price | Market cap | P/E | ROE |
| --- | --- | --- | --- | --- |
| [Tejnaksh](https://app.pivotnow.in/stock/TEJNAKSH) | — | ₹29 Cr | — | — |
| [SAMSRITA LABS](https://app.pivotnow.in/stock/SAMSRITA) | — | ₹28 Cr | — | — |
| [Parmax Pharma](https://app.pivotnow.in/stock/PARMAX) | — | ₹25 Cr | — | — |
| [Transgene Biote](https://app.pivotnow.in/stock/TRABI) | — | ₹23 Cr | — | — |
| [Hamps Bio](https://app.pivotnow.in/stock/HAMPS) | — | ₹22 Cr | — | — |
| [Rekvina Labs](https://app.pivotnow.in/stock/VINRKLB) | — | ₹22 Cr | — | — |

## Questions and answers

### What is the market cap of SUPHA PHARMACHE?

SUPHA PHARMACHE's market capitalisation is ₹25 Cr (₹25 Cr) at the 22 Oct 2026 close, ranking 3477th among the NSE companies Pivot tracks.

### What is the ROE and ROCE of SUPHA PHARMACHE?

Return on equity was 4.9% in FY25 and return on capital employed was 22.0% in FY25 (consolidated figures).

### Is SUPHA PHARMACHE a debt-free company?

No. SUPHA PHARMACHE's debt-to-equity ratio was 26.01 in FY25, with total debt of ₹0 Cr.

### What were SUPHA PHARMACHE's latest quarterly results?

For Q2 FY26 (quarter ended 30 Sep 2025), SUPHA PHARMACHE reported revenue of ₹111 Cr and net profit of ₹9 Cr.

### What is the shareholding pattern of SUPHA PHARMACHE?

As of 31 Dec 2025: promoters 1.13%, foreign institutions 1.70%, non-institutions 97.17%.

### Who are SUPHA PHARMACHE's competitors?

The listed Pharma & Healthcare companies closest to SUPHA PHARMACHE by market cap are Tejnaksh, SAMSRITA LABS, Parmax Pharma, Transgene Biote, Hamps Bio and Rekvina Labs.

### Is SUPHA PHARMACHE a good stock to buy?

Pivot does not give buy or sell recommendations. This page sets out SUPHA PHARMACHE's price history, valuation, profitability, quarterly results and ownership so you can judge it yourself, and Pivot's chart lets you test a strategy on SUPHA against its own history before risking money. This is analysis, not financial advice.

---

Sources: NSE end-of-day bars (Pivot's market data store); Company filings via Moneycontrol; Exchange shareholding-pattern filings. This is analysis, not financial advice. Pivot is not a broker or a SEBI-registered investment adviser.